Reference : Current options for the management of postmenopausal osteoporosis.
Scientific journals : Article
Human health sciences : General & internal medicine
Current options for the management of postmenopausal osteoporosis.
LECART, Marie-Paule mailto [Centre Hospitalier Universitaire de Liège - CHU > > Algologie - soins palliatifs]
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé]
Expert Opinion on Pharmacotherapy
Ashley Publications Ltd
Yes (verified by ORBi)
United Kingdom
[en] INTRODUCTION: Osteoporosis is a well-recognized disease with severe consequences if left untreated. The prevention of osteoporosis-associated fractures should include fall prevention, calcium supplementation and life-style advice, as well as pharmacological therapy using agents with proven antifracture efficacy. AREAS COVERED: This manuscript offers an evidence-based critical assessment of the currently available efficacy data on all new chemical entities that have been granted a marketing authorization for the management of primary osteoporosis in women. EXPERT OPINION: The availability of new therapeutic agents makes clinical decision making in osteoporosis more complex. Therapeutic decisions should be based on a balance between the benefits and risks of treatment, which must be carefully considered in each particular case, both by the physician and the patient. Indeed, no single agent is appropriate for all patients. Therefore, treatment decisions should be made on a tailor-made basis, taking into account all measures of treatment effect and risk, before making informed judgments about the best individual treatment option.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Current options for the management of postmenopausal osteoporosis.pdfPublisher postprint353.99 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.